18 research outputs found
Phase I/II study of weekly LOC-paclitaxel (LOC-pac) injection in patients (pts) with metastatic melanoma (MM).
Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab.
Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma.
Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors.
Phase I study of ipilimumab (IPI) with biochemotherapy (BCT) for chemonaïve patients with metastatic melanoma (MM).
A single-institution experience with the pembrolizumab (PEM) Expanded Access Program (EAP).
Continued evaluation of a 31-gene expression profile test (GEP) for prediction of distant metastasis (DM) in cutaneous melanoma (CM).
BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma.
Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical benefit regardless of site of origin, mutation status, or prior checkpoint blockade.
Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma
1 page(s